Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John J. Boyce | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | - |
Joseph Wilkinson | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | - |
Philippe Mourere | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | 1 ans |
Scott Sherman | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | - |
Anurag Kondapalli | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | - |
Elouise P. Manhertz | M | - |
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 6 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Qimin Quan
- Réseau Personnel